CMC & ManufacturingLast reviewed April 2026

Compendial Method(Compendial Method)

An analytical method published in an official pharmacopoeia (USP, Ph. Eur., JP) that serves as the recognized standard for testing a specific article.

Usage Examples

The drug product release test for dissolution used USP <711> Apparatus 2 compendial method.
An alternative HPLC method was validated to replace the compendial assay showing improved sensitivity and shorter run time.

What is Compendial Method?

Compendial methods are analytical procedures published in official pharmacopoeias — USP (United States Pharmacopeia), Ph. Eur. (European Pharmacopoeia), JP (Japanese Pharmacopoeia) — and serve as the legal and scientific standard for testing articles with monographs in those pharmacopoeias. FDA accepts compendial methods without additional validation when used per the monograph; EMA and PMDA apply similar acceptance to Ph. Eur. and JP methods respectively.

Manufacturers may use validated non-compendial methods (often called "alternative methods") provided they demonstrate equivalence to or superiority over the compendial method. Many modern analytical methods (HPLC-UV for impurities, LC-MS for residual solvents, Karl Fischer for water content) have both compendial and non-compendial variants. Regulatory submissions typically reference the compendial method being used; alternative methods require full validation documentation in Module 3.2.S.4.3 or 3.2.P.5.3.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside USP GENERAL NOTICES, PH EUR GENERAL NOTICES, 21 CFR 211 194.

FDAICHHealth Canada

When This Matters

The drug product release test for dissolution used USP <711> Apparatus 2 compendial method.
An alternative HPLC method was validated to replace the compendial assay showing improved sensitivity and shorter run time.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

USP GENERAL NOTICESPH EUR GENERAL NOTICES21 CFR 211 194

Frequently Asked Questions

Compendial methods used per the published monograph do not require re-validation of the method itself — pharmacopoeia validation suffices. However, verification that the method works in the specific manufacturer's laboratory (suitability) is required per USP <1226> or equivalent.

Yes, with equivalence demonstration. Alternative methods must meet or exceed the compendial method's performance (accuracy, precision, specificity, LOQ, etc.). In case of dispute, the compendial method is typically the referee method.

All three are official pharmacopoeias with legal status in their respective regions (US, EU/EEA, Japan). Methods are often similar but not identical. ICH Q4 harmonization efforts align methods where possible. Manufacturers filing globally often reference the pharmacopoeia applicable to each region.